An Integrated mRNA and microRNA Expression Signature for Glioblastoma Multiforme Prognosis

Although patients with Glioblastoma multiforme (GBM) have grave prognosis, significant variability in patient outcome is observed. The objective of this study is to identify a molecular signature for GBM prognosis. We subjected 355 mRNA and microRNA expression profiles to elastic net-regulated Cox regression for identification of an integrated RNA signature for GBM prognosis. A prognostic index (PI) was generated for patient stratification. Survival comparison was conducted by Kaplan-Meier method and a general multivariate Cox regression procedure was applied to evaluate the independence of the PI. The abilities and efficiencies of signatures to predict GBM patient outcome was assessed and compared by the area under the curve (AUC) of the receiver-operator characteristic (ROC). An integrated RNA prognostic signature consisted by 4 protective mRNAs, 12 risky mRNAs, and 1 risky microRNA was identified. Decreased survival was associated with being in the high-risk group (hazard ratio = 2.864, P<0.0001). The prognostic value of the integrated signature was validated in five independent GBM expression datasets (n = 201, hazard ratio = 2.453, P<0.0001). The PI outperformed the known clinical factors, mRNA-only, and miRNA-only prognostic signatures for GBM prognosis (area under the ROC curve for the integrated RNA, mRNA-only, and miRNA-only signatures were 0.828, 0.742, and 0.757 at 3 years of overall survival, respectively, P<0.0001 by permutation test). We describe the first, to our knowledge, robust transcriptome-based integrated RNA signature that improves the current GBM prognosis based on clinical variables, mRNA-only, and miRNA-only signatures.

[1]  Y. Fujii,et al.  Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. , 2011, International journal of oncology.

[2]  Gabriele Schackert,et al.  Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[3]  P. López-Romero.  Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library , 2011, BMC Genomics.

[4]  N. Seidah,et al.  The C-terminal Region of proSAAS Is a Potent Inhibitor of Prohormone Convertase 1* , 2000, The Journal of Biological Chemistry.

[5]  M. Yuan,et al.  Model selection and estimation in regression with grouped variables , 2006 .

[6]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[7]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[8]  A. Varki,et al.  Glycosylation Changes in Cancer , 2009 .

[9]  I. Lindberg,et al.  The SAAS granin exhibits structural and functional homology to 7B2 and contains a highly potent hexapeptide inhibitor of PC1 , 2000, FEBS letters.

[10]  S. Horvath,et al.  Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age , 2008, BMC Medical Genomics.

[11]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[12]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[13]  Andreas Keller,et al.  A specific miRNA signature in the peripheral blood of glioblastoma patients , 2011, Journal of neurochemistry.

[14]  Biaoyang Lin,et al.  A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. , 2012, Omics : a journal of integrative biology.

[15]  Nandini A. Sahasrabuddhe,et al.  SILAC‐based quantitative proteomic analysis of gastric cancer secretome , 2013, Proteomics. Clinical applications.

[16]  P. Day,et al.  Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. , 2013, Neuro-oncology.

[17]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[18]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[19]  Y. Kanai,et al.  Expression of N-cadherin and alpha-catenin in astrocytomas and glioblastomas. , 1995, British Journal of Cancer.

[20]  D. Louis,et al.  Activation of STAT3, MAPK, and AKT in Malignant Astrocytic Gliomas: Correlation With EGFR Status, Tumor Grade, and Survival , 2006, Journal of neuropathology and experimental neurology.

[21]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[22]  R. Abounader,et al.  Abstract 3165: microRNA-148a: A novel oncogenic microRNA in glioblastoma , 2012 .

[23]  J. Dixon,et al.  The Outer Mitochondrial Membrane Protein mitoNEET Contains a Novel Redox-active 2Fe-2S Cluster* , 2007, Journal of Biological Chemistry.

[24]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[25]  Dimitris Anastassiou,et al.  A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma , 2012, PloS one.

[26]  Sujaya Srinivasan,et al.  A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma , 2011, PloS one.

[27]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[28]  Tao Jiang,et al.  A Systems Biology-Based Gene Expression Classifier of Glioblastoma Predicts Survival with Solid Tumors , 2009, PloS one.

[29]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  Arnoldo Frigessi,et al.  BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm305 Gene expression Predicting survival from microarray data—a comparative study , 2022 .

[32]  Y. Fujii,et al.  Gene expression signature‐based prognostic risk score in patients with glioblastoma , 2013, Cancer science.

[33]  Ituro Inoue,et al.  Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.

[34]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[35]  K. Robertson,et al.  DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. , 2009, Cancer research.

[36]  T. Santa-Coloma,et al.  CISD1 codifies a mitochondrial protein upregulated by the CFTR channel. , 2008, Biochemical and biophysical research communications.

[37]  M. West,et al.  Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.

[38]  K. Ligon,et al.  Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma , 2005, Journal of neuropathology and experimental neurology.

[39]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[40]  Wei Zhang,et al.  Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. , 2009, Neuro-oncology.

[41]  Wei-Min Liu,et al.  Analysis of high density expression microarrays with signed-rank call algorithms , 2002, Bioinform..

[42]  T. Wakabayashi,et al.  Current Trends in Targeted Therapies for Glioblastoma Multiforme , 2012, Neurology research international.

[43]  R. Tibshirani,et al.  Strong rules for discarding predictors in lasso‐type problems , 2010, Journal of the Royal Statistical Society. Series B, Statistical methodology.

[44]  Hyunsoo Kim,et al.  Predicting survial by cancer pathway gene expression profiles in the TCGA , 2012, 2012 IEEE International Conference on Bioinformatics and Biomedicine Workshops.

[45]  Harish Srinivasan,et al.  A Fourteen Gene GBM Prognostic Signature Identifies Association of Immune Response Pathway and Mesenchymal Subtype with High Risk Group , 2013, PloS one.

[46]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[47]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .